William Y K Hwang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7249464/publications.pdf

Version: 2024-02-01

165 papers	4,999 citations	147801 31 h-index	106344 65 g-index
167 all docs	167 docs citations	167 times ranked	9838 citing authors

#	Article	IF	Citations
1	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	2.9	766
2	Immunogenicity of engineered antibodies. Methods, 2005, 36, 3-10.	3.8	519
3	Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. Immunity, 2018, 48, 364-379.e8.	14.3	450
4	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). European Journal of Immunology, 2021, 51, 2708-3145.	2.9	198
5	A Meta-Analysis of Unrelated Donor Umbilical Cord Blood Transplantation versus Unrelated Donor Bone Marrow Transplantation in Adult and Pediatric Patients. Biology of Blood and Marrow Transplantation, 2007, 13, 444-453.	2.0	156
6	Combinatorial Single-Cell Analyses of Granulocyte-Monocyte Progenitor Heterogeneity Reveals an Early Uni-potent Neutrophil Progenitor. Immunity, 2020, 53, 303-318.e5.	14.3	153
7	The CD4^{â˜'}CD8^{â˜'}MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8⁺MAIT cell pool. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11513-E11522.	7.1	147
8	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infectious Diseases, The, 2019, 19, 988-1000.	9.1	136
9	Electrospun nanofiber scaffolds for rapid and rich capture of bone marrow-derived hematopoietic stem cells. Biomaterials, 2008, 29, 2096-2103.	11.4	131
10	Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. Cell, 2019, 179, 736-749.e15.	28.9	126
11	Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007, 13, 1016-1021.	2.0	115
12	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. Journal of Clinical Oncology, 2019, 37, 367-374.	1.6	110
13	Understanding the Psychological Impact of COVID-19 Pandemic on Patients With Cancer, Their Caregivers, and Health Care Workers in Singapore. JCO Global Oncology, 2020, 6, 1494-1509.	1.8	95
14	Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology, 2019, 156, 1862-1876.e9.	1.3	92
15	Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods, 2005, 36, 35-42.	3.8	82
16	Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica, 2011, 96, 942-947.	3.5	75
17	The N3XT Approach to Energy-Efficient Abundant-Data Computing. Proceedings of the IEEE, 2019, 107, 19-48.	21.3	71
18	The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplantation, 2012, 47, 957-966.	2.4	68

#	Article	IF	Citations
19	Mesenchymal Stem Cells Secreting Angiopoietin-Like-5 Support Efficient Expansion of Human Hematopoietic Stem Cells Without Compromising Their Repopulating Potential. Stem Cells and Development, 2011, 20, 1371-1381.	2.1	61
20	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood, 2021, 138, 1429-1440.	1.4	54
21	Expansion of Human Cord Blood Hematopoietic Stem Cells for Transplantation. Cell Stem Cell, 2010, 7, 427-428.	11.1	52
22	A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. Bone Marrow Transplantation, 2015, 50, 334-340.	2.4	50
23	Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematology,the, 2015, 2, e326-e333.	4.6	50
24	Hyperdimensional Computing Exploiting Carbon Nanotube FETs, Resistive RAM, and Their Monolithic 3D Integration. IEEE Journal of Solid-State Circuits, 2018, 53, 3183-3196.	5.4	49
25	Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy. Leukemia, 2019, 33, 1487-1500.	7.2	48
26	Expansion and Homing of Umbilical Cord Blood Hematopoietic Stem and Progenitor Cells for Clinical Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1008-1019.	2.0	46
27	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia, 2020, 34, 3413-3419.	7.2	42
28	Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2005, 159, 129-136.	1.0	40
29	A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy, 2012, 14, 851-859.	0.7	40
30	Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group. Bone Marrow Transplantation, 2010, 45, 1682-1691.	2.4	39
31	Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Annals of Oncology, 2012, 23, 421-426.	1.2	37
32	A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2004, 34, 51-56.	2.4	30
33	Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 167-172.	0.9	27
34	Nonhuman primate allogeneic hematopoietic stem cell transplantation by intraosseus vs intravenous injection: Engraftment, donor cell distribution, and mechanistic basis. Experimental Hematology, 2008, 36, 1556-1566.	0.4	25
35	Ex Vivo Expansion of CD34+CD90+CD49f+ Hematopoietic Stem and Progenitor Cells from Non-Enriched Umbilical Cord Blood with Azole Compounds. Stem Cells Translational Medicine, 2018, 7, 376-393.	3.3	23
36	Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	23

#	Article	IF	Citations
37	Protective role of functionalized single walled carbon nanotubes enhance ex vivo expansion of hematopoietic stem and progenitor cells in human umbilical cord blood. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 1304-1316.	3.3	22
38	Mesenchymal stromal cell supported umbilical cord blood ex vivo expansion enhances regulatory T cells and reduces graft versus host disease. Cytotherapy, 2013, 15, 610-619.	0.7	22
39	Distinct Responses of Stem Cells to Telomere Uncappingâ€"A Potential Strategy to Improve the Safety of Cell Therapy. Stem Cells, 2016, 34, 2471-2484.	3.2	22
40	Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia Following Nonmyeloablative Conditioning Using 200-cGy Total Body Irradiation and Fludarabine. Biology of Blood and Marrow Transplantation, 2006, 12, 887-890.	2.0	21
41	Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singaporeâ€™s healthcare system perspective. Journal of Medical Economics, 2020, 23, 1321-1329.	2.1	20
42	Low-dose insulin-like growth factor binding proteins 1 and 2 and angiopoietin-like protein 3 coordinately stimulate ex vivo expansion of human umbilical cord blood hematopoietic stem cells as assayed in NOD/SCID gamma null mice. Stem Cell Research and Therapy, 2014, 5, 71.	5.5	19
43	Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group. Bone Marrow Transplantation, 2016, 51, 933-937.	2.4	18
44	Respiratory virus infection after allogeneic hematopoietic stem cell transplant in a tropical center: Predictive value of the immunodeficiency scoring index. Transplant Infectious Disease, 2017, 19, e12693.	1.7	18
45	Successful treatment of primary granulocytic sarcoma by non-myeloablative stem cell transplant. Leukemia and Lymphoma, 2006, 47, 159-162.	1.3	17
46	Pre-transplant achievement of negativity in minimal residual disease and Frenchâ€"Americanâ€"British L1 morphology predict superior outcome after allogeneic transplant for Philadelphia chromosome positive acute lymphoblastic leukemia: an analysis of Southeast Asian patients. Leukemia and Lymphoma, 2015, 56, 1362-1369.	1.3	17
47	An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. American Journal of Hematology, 2010, 85, 752-756.	4.1	16
48	Comparing peripheral blood stem cell collection using the COBE Spectra, Haemonetics MCS+, and Baxter Amicus. Transfusion and Apheresis Science, 2012, 47, 345-350.	1.0	16
49	Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 688-695.	2.0	16
50	Fanconi's Anemia in Adulthood: Chemoradiation-Induced Bone Marrow Failure and a Novel FANCA Mutation Identified by Targeted Deep Sequencing. Journal of Clinical Oncology, 2011, 29, e591-e594.	1.6	15
51	HLA Haplotypes in Singapore: A Study of Mothers and Their Cord Blood Units. Human Immunology, 2007, 68, 430-438.	2.4	14
52	Intercellular cytosolic transfer correlates with mesenchymal stromal cell rescue of umbilical cord blood cell viability during ex vivo expansion. Cytotherapy, 2012, 14, 1064-1079.	0.7	14
53	Study of gene expression profile during cord bloodâ€associated megakaryopoiesis. European Journal of Haematology, 2008, 81, 196-208.	2.2	13
54	Effect of missing killer-immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients. Bone Marrow Transplantation, 2010, 45, 1031-1037.	2.4	13

#	Article	IF	Citations
55	Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer/T-cell lymphoma. Leukemia and Lymphoma, 2011, 52, 1382-1386.	1.3	13
56	Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia. Haematologia, 2001, 31, 73-80.	0.3	12
57	Unrelated peripheral blood and cord blood hematopoietic stem cell transplants for thalassemia major. American Journal of Hematology, 2004, 75, 209-212.	4.1	12
58	BK-virus prophylaxis: still no answer. Bone Marrow Transplantation, 2013, 48, 1362-1363.	2.4	12
59	The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2018, 59, 2336-2341.	1.3	12
60	Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 1971-1980.	2.0	12
61	A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL). Blood, 2014, 124, 503-503.	1.4	12
62	Biological characteristics of megakaryocytes: Specific lineage commitment and associated disorders. International Journal of Biochemistry and Cell Biology, 2006, 38, 1821-1826.	2.8	11
63	Cotransplantation of ExÂVivo Expanded and Unexpanded Cord Blood Units in Immunodeficient MiceÂUsing Insulin Growth Factor Binding Protein-2â€“Augmented Mesenchymal Cell Cocultures. Biology of Blood and Marrow Transplantation, 2012, 18, 674-682.	2.0	11
64	Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation. Bone Marrow Transplantation, 2013, 48, 1506-1509.	2.4	11
65	Minimizing transmission of COVID-19 while delivering optimal cancer care in a National Cancer Centre. Journal of Cancer Policy, 2020, 25, 100241.	1.4	11
66	Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. Bone Marrow Transplantation, 2003, 31, 305-308.	2.4	10
67	Successful Treatment of Idiopathic Hypereosinophilic Syndrome with Imatinib Mesylate: A Case Report. International Journal of Hematology, 2004, 80, 75-77.	1.6	10
68	Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant Using the Fludarabine and Low-Dose Total-Body Irradiation 200-cGy. Biology of Blood and Marrow Transplantation, 2007, 13, 790-805.	2.0	10
69	Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells. Journal of Hematology and Oncology, 2008, 1, 19.	17.0	10
70	The Impact of COVID-19 on Cancer Care in the Post Pandemic World: Five Major Lessons Learnt from Challenges and Countermeasures of Major Asian Cancer Centres. Asian Pacific Journal of Cancer Prevention, 2021, 22, 681-690.	1.2	10
71	Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. Oncotarget, 2017, 8, 25455-25468.	1.8	10
72	Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling?evaluation of risks and benefits. Annals of Hematology, 2004, 83, 286-294.	1.8	9

#	Article	IF	Citations
73	Identification of nine new HLA class I alleles in volunteers from the Singapore stem cell donor registries. Tissue Antigens, 2006, 68, 518-520.	1.0	9
74	Successful Autologous Hematopoietic Stem Cell Transplantations for Severe Multiple Sclerosis with Fludarabine and Cyclophosphamide Conditioning. International Journal of Hematology, 2006, 83, 368-369.	1.6	9
75	Mitochondrial superoxide reduction and cytokine secretion skewing by carbon nanotube scaffolds enhance ex vivo expansion of human cord blood hematopoietic progenitors. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1643-1656.	3.3	9
76	What We Learned From Plasma BK-Virus Monitoring in Allogeneic Hematopoietic Transplant Recipients. Transplantation, 2016, 100, e17-e18.	1.0	9
77	Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 117-121.	0.4	9
78	Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singaporeâ€™s private insurance payerâ€™s perspective. Journal of Medical Economics, 2021, 24, 637-653.	2.1	9
79	An Asian Body to Tackle Cancers in Asia â€“ The Asian National Cancer Centers Alliance. Asian Pacific Journal of Cancer Prevention, 2020, 21, 1207-1212.	1.2	9
80	Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma. Bone Marrow Transplantation, 2010, 45, 1625-1630.	2.4	8
81	Inadvertent completely HLA-mismatched allogeneic unrelated bone marrow transplant: lessons learned. Bone Marrow Transplantation, 2016, 51, 1016-1018.	2.4	8
82	Recommendations to improve the clinical adoption of NGSâ€based cancer diagnostics in Singapore. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 222-231.	1.1	8
83	Severe acute graft-versus-host disease occurring after syngeneic BMT for AML in a patient not given prior cyclosporin A therapy. Bone Marrow Transplantation, 2000, 25, 205-207.	2.4	7
84	Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2007, 48, 72-79.	1.3	7
85	Acarbose is an effective treatment for severe hypertriglyceridemia secondary to <scp>l</scp>-asparaginase and dexamethasone. Leukemia and Lymphoma, 2012, 53, 1245-1246.	1.3	7
86	Safety of Living Donation of Hematopoietic Stem Cells. Transplantation, 2016, 100, 1329-1331.	1.0	7
87	Recurrent trichosporonosis with central nervous system involvement in an allogeneic hematopoietic stem cell transplant recipient. Transplant Infectious Disease, 2016, 18, 768-772.	1.7	7
88	Coming Up N3XT, After 2D Scaling of Si CMOS. , 2018, , .		7
89	Stem cell transplantation programme at Singapore General Hospital. Bone Marrow Transplantation, 2008, 42, S121-S124.	2.4	6
90	3D nanosystems enable embedded abundant-data computing. , 2017, , .		6

#	Article	IF	Citations
91	Donorâ€type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant. Transfusion, 2019, 59, 335-339.	1.6	6
92	Cancer Versus COVID-19: A Coordinated Disease Outbreak Response System (DORS) to Combat COVID-19 at the National Cancer Centre Singapore. Annals of the Academy of Medicine, Singapore, 2020, 49, 807-809.	0.4	6
93	Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective. ClinicoEconomics and Outcomes Research, 2022, Volume 14, 333-355.	1.9	6
94	Decoupling of normal CD40/interleukin-4 immunoglobulin heavy chain switch signal leads to genomic instability in SGH-MM5 and RPMI 8226 multiple myeloma cell lines. Leukemia, 2006, 20, 715-723.	7.2	5
95	Characterization of new HLAâ€B and â€DRB1 alleles from Singapore. Tissue Antigens, 2009, 73, 75-76.	1.0	5
96	A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02. Pharmacogenomics, 2016, 17, 1235-1243.	1.3	5
97	Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity. Blood, 2018, 132, 2676-2676.	1.4	5
98	Novel HLA class I and II alleles identified during routine registry typing in 2010. Tissue Antigens, 2011, 78, 263-266.	1.0	4
99	Longâ€term renal outcome after allogeneic hemopoietic stem cell transplant: A comprehensive analysis of risk factors in an Asian patient population. Clinical Transplantation, 2017, 31, e12920.	1.6	4
100	Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma. Annals of Hematology, 2017, 96, 1959-1960.	1.8	4
101	An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication. Bone Marrow Transplantation, 2017, 52, 363-371.	2.4	4
102	Early Outcomes of a National Cancer Center's Strategy Against COVID-19 Executed Through a Disease Outbreak Response Taskforce. JCO Oncology Practice, 2021, 17, e343-e354.	2.9	4
103	Mixed Phenotype Acute Leukemia with Low Hypodiploidy in a Pediatric Patient. Journal of Pediatric Oncology, 2015, 3, 24-28.	0.1	4
104	Myelodysplastic syndrome with transformation to AML-M7 in a 46,XX male patient. Cancer Genetics and Cytogenetics, 2002, 136, 153-154.	1.0	3
105	Use of ultraviolet-light irradiated multiple myeloma cells as immunogens to generate tumor-specific cytolytic T lymphocytes. Journal of Immune Based Therapies and Vaccines, 2008, 6, 2.	2.4	3
106	Characterization of hemopoietic engraftment kinetics and development of secondary cytopenia in AML post auto-SCT and its correlation with survival outcome. Bone Marrow Transplantation, 2009, 44, 175-183.	2.4	3
107	WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients. Annals of Hematology, 2015, 94, 761-769.	1.8	3
108	Proptosis in a Patient With Known Graft Versus Host Disease. Ophthalmic Plastic and Reconstructive Surgery, 2019, 35, e142-e145.	0.8	3

#	Article	IF	Citations
109	Facilitating timely cancer care in a surgical oncology subspecialty unit during the pandemic and recovery phase of the COVID era. Asian Journal of Surgery, 2020, 43, 965-966.	0.4	3
110	Combined interstitial and surface high-dose-rate brachytherapy treatment of squamous cell carcinoma of the hand. Journal of Contemporary Brachytherapy, 2020, 12, 48-52.	0.9	3
111	Use of Immunoglobulin Infusions in the Management of Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma.. Blood, 2006, 108, 5097-5097.	1.4	3
112	Allogeneic haematopoietic stem cell transplantation without a matched sibling donor: current options and future potential. Annals of the Academy of Medicine, Singapore, 2009, 38, 340-6.	0.4	3
113	Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Advances in Hematology, 2009, 2009, 1-4.	1.0	2
114	Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation. Bone Marrow Transplantation, 2012, 47, 181-189.	2.4	2
115	Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation. BMC Hematology, 2015, 15, 8.	2.6	2
116	World Cancer Day 2021: Remembering the ongoing cancer pandemic. Annals of the Academy of Medicine, Singapore, 2021, 50, 107-108.	0.4	2
117	Editorial: Recent Developments in Haploidentical Hematopoietic Cell Transplantation: Therapy and Complications. Frontiers in Immunology, 2021, 12, 746221.	4.8	2
118	Cytokine Induced Killer Cells Are Feasible and Safe for Both Autologous and Allogeneic Applications in Patients with Haematological Malignancies. Blood, 2008, 112, 2917-2917.	1.4	2
119	Treatment of blastic plasmacytoid dendritic cell neoplasms with cord blood transplants. Clinical Advances in Hematology and Oncology, 2011, 9, 569-70.	0.3	2
120	Studies of Wilmsâ€™ Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore. Biomarker Insights, 2007, 2, 117727190700200.	2.5	1
121	Cord blood unit factors influencing transplant outcomes from the Asian multiethnic Singapore Cord Blood Bank. Bone Marrow Transplantation, 2015, 50, 1256-1258.	2.4	1
122	Preparing for the Next Pandemic: An Asian National Cancer Centers Alliance (ANCCA) Initiative. Asian Pacific Journal of Cancer Prevention, 2021, 22, 2945-2950.	1.2	1
123	Low Dose Dexamethasone and Thalidomide with Higher Frequency Zoledronic Acid (dtZ) for Multiple Myeloma.. Blood, 2004, 104, 4915-4915.	1.4	1
124	Outpatient-Based Therapy with Oral Fludarabine and Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2006, 108, 4992-4992.	1.4	1
125	Small Molecule Based Ex Vivo Expansion of CD34+CD90+CD49f+ Hematopoietic Stem & Progenitor Cells from Non-Enriched Umbilical Cord Blood Mononucleated Cells. Blood, 2016, 128, 2321-2321.	1.4	1
126	High Dose Cytarabine Is Superior to Intermediate Dose Cytarabine As Post-Remission Therapy for Younger Patients with Favorable Risk Acute Myeloid Leukemia. Blood, 2016, 128, 4032-4032.	1.4	1

#	Article	IF	Citations
127	High Response and Complete Remission Rates in Relapsed/Refractory Multiple Myeloma Treated with Bortezomib, Thalidomide, Dexamethasone and Zoledronic Acid (VTD-Z) Combination Therapy.. Blood, 2005, 106, 5127-5127.	1.4	1
128	Banking of Cord Blood. , 2010, , 291-320.		1
129	Mefloquine Effectively Targets Blast Phase Chronic Myeloid Leukemia through Inducing Oxidative Stress and Lysosomal Disruption. Blood, 2016, 128, 5426-5426.	1.4	1
130	Blood stem cell donation: a model for worldwide cooperation in transplantation. Annals of the Academy of Medicine, Singapore, 2014, 43, 294-5.	0.4	1
131	World Cancer Day 2021: Remembering the ongoing cancer pandemic. Annals of the Academy of Medicine, Singapore, 2021, 50, 107-108.	0.4	1
132	High-dose chemotherapy and autologous stem cell rescue for acute myeloid leukemia remains a safe, effective, and valid option. Transplantation Proceedings, 2000, 32, 2464-2466.	0.6	0
133	124: Mesenchymal Stem Cells Support ex vivo Umbilical Cord Blood Expansion by a Contact-Dependent Anti-Apoptotic Effect. Biology of Blood and Marrow Transplantation, 2008, 14, 47-48.	2.0	0
134	The Effect of Donor Cytomegalovirus (CMV) Serologic Status on Outcome and Survival in Patients Undergoing Allogenic Stem Cell Transplantation in the Era of CMV-Preemptive Therapy. Biology of Blood and Marrow Transplantation, 2011, 17, S280-S281.	2.0	0
135	Retrospective Analysis of Effectiveness of Veno-Occlusive Prophylaxis Guidelines Implemented for Patients Receiving Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, S191.	2.0	0
136	Treatment of advanced stage <scp>H</scp>odgkin lymphoma â€“ it's all about riskâ€benefit. British Journal of Haematology, 2012, 159, 113-115.	2.5	0
137	Evaluation of Revised Vaccination Guideline for Hematopoietic Cell Transplant Patients in Singapore General Hospital. Biology of Blood and Marrow Transplantation, 2014, 20, S292-S293.	2.0	0
138	Race Influences the Response to Conventional Induction Chemotherapy in Asian Patients with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, S187-S188.	2.0	0
139	Transplant Outcomes and Early Relapse after Novel and Non-Novel Agent Induction: An Analysis By Singapore Myeloma Working Group. Biology of Blood and Marrow Transplantation, 2016, 22, S221.	2.0	0
140	Personalized T cell therapy against HBV-related hepatocellularcarcinoma. Journal of Hepatology, 2018, 68, S12-S13.	3.7	0
141	PS-141-CyTOF-based immune monitoring of HBV-HCC patients receiving autologous anti-tumour T-cell therapy. Journal of Hepatology, 2019, 70, e89-e90.	3.7	0
142	Hematopoietic Stem Cell Expansion. Annals of Oncology, 2019, 30, vi74.	1.2	0
143	Harnessing MSC Osteoprogenitor Subpopulations to Augment Hematopoietic Transplantations. Biology of Blood and Marrow Transplantation, 2019, 25, S166.	2.0	0
144	So, you want to be a doctor?. Internal Medicine Journal, 2019, 49, 407-408.	0.8	0

#	Article	IF	Citations
145	Mobilization kinetics of peripheral blood stem cells with rescue plerixafor â€“ real-world experience from a single center. Leukemia and Lymphoma, 2020, 61, 1740-1743.	1.3	0
146	CD40 Ligand Stimulation of Multiple Myeloma Cells Results in Upregulation of Surface Expressed Heat Shock Proteins and Increased Antigenicity.. Blood, 2004, 104, 3351-3351.	1.4	0
147	Decoupling of Normal CD40 / Interleukin-4 Immunoglobulin Heavy Chain Switch Signal Leads to Genomic Instability in RPMI 8226 and SGH-MM5 Multiple Myeloma Cell Lines.. Blood, 2004, 104, 1424-1424.	1.4	0
148	Nutritional Anemias. , 2004, , 559-570.		0
149	Campath-1H-Regulated Ex Vivo Expansion of Cord Blood: Selection of Stem Cells, Depletion of Lymphocytes and Preferential Expansion of Myeloid, Megakaryocytic and Erythroid Precursors.. Blood, 2006, 108, 3644-3644.	1.4	0
150	The Haemophagocytic Syndrome Re-Visited: A Unique Asian Perspective.. Blood, 2006, 108, 3840-3840.	1.4	0
151	Comparison of Donor Cell Homing Efficiency between Intraosseus and Intravenous Injection in Primate Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 3206-3206.	1.4	0
152	Factors Influencing Responsiveness to Bortezomib in Patients with Multiple Myeloma Suggest a Possible Role for Host Immunocompetency.. Blood, 2006, 108, 5100-5100.	1.4	0
153	Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response. Blood, 2010, 116, 3056-3056.	1.4	0
154	Functionalized Carbon Nanotubes Increase the Viability of Post-Thaw Cord Blood Cells and Enhance the Overall Hematopoietic Progenitor Cell Expansion in Ex Vivo Culture. Blood, 2011, 118, 1327-1327.	1.4	0
155	Effectiveness of Ursodeoxycholic Acid As Prophylactic Agent Against Hepatic Sinusoidal Obstruction Syndrome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Treatment of Hematological Malignancies. Blood, 2012, 120, 4165-4165.	1.4	0
156	Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response. Blood, 2012, 120, 3669-3669.	1.4	0
157	Role of surveillance imaging in the management of peripheral T-cell lymphomas.. Journal of Clinical Oncology, 2014, 32, 8543-8543.	1.6	0
158	Reduction of Mitochondrial Superoxide By Carbon Nanotube Scaffolds Enhances Ex Vivo Expansion of Human Cord Blood Progenitor Cells. Blood, 2014, 124, 2928-2928.	1.4	0
159	Impact of Post-Remission Consolidation Modalities in the Clinical Outcomes of Acute Myeloid Leukemia Patients in First Remission - Is There a Role for Autologous Hematopoietic Stem Cell Transplant?. Blood, 2015, 126, 3184-3184.	1.4	0
160	Mechanism of Action of Azacytidine in Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 4315-4315.	1.4	0
161	Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort. Blood, 2016, 128, 1871-1871.	1.4	0
162	In Vitro Expanded Î³Î´ T Cells Derived from Cord Blood Induce Potent and Specific Cytotoxicity Against Human Acute Myeloid Leukemia Cells. Blood, 2016, 128, 2168-2168.	1.4	0

#	Article	IF	Citations
163	Unmanipulated Haploidentical Transplant Followed By Post-Transplant Cyclophosphamide and Selective Ex Vivo T-Cell Depleted Haploidentical Transplant Results in Comparable Outcome As Unrelated Cord Blood Transplant for Adults with Haematological Malignancies- a Multicenter Study in Singapore. Blood, 2019, 134, 4588-4588.	1.4	0
164	A Biophysically Defined MSC Subpopulation for Enhanced Homing and Immunosuppression. Blood, 2019, 134, 2078-2078.	1.4	0
165	High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore. Blood, 2019, 134, 4509-4509.	1.4	0